# Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias

> **NCT04786223** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Val Lowe** · enrollment: 125 (estimated)

## Conditions studied

- Alzheimer Disease
- Lewy Body's Dementia

## Interventions

- **DRUG:** C-11 ER-176
- **DIAGNOSTIC_TEST:** Blood Test

## Key facts

- **NCT ID:** NCT04786223
- **Lead sponsor:** Val Lowe
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-03-30
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04786223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04786223, "Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04786223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*